39161-85-8

Basic information

• Product Name: 2-MERCAPTOPHENYLACETIC ACID
• Synonyms: 2-MERCAPTOBENZENEACETIC ACID;2-MERCAPTOPHENYLACETIC ACID;o-Mercaptophenylacetic Acid
• CAS NO: 39161-85-8
• Molecular Formula: C₈H₈O₂S
• Molecular Weight: 168.21
• Product Categories: Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 39161-85-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 90-92°C
• Boiling Point: 334.7°C at 760 mmHg
• Flash Point: 156.2°C
• Appearance: /
• Density: 1.299g/cm³
• Vapor Pressure: 4.95E-05mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Stability: Air Sensitive, not stable in DMSO
• CAS DataBase Reference: 2-MERCAPTOPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-MERCAPTOPHENYLACETIC ACID(39161-85-8)
• EPA Substance Registry System: 2-MERCAPTOPHENYLACETIC ACID(39161-85-8)

Safety Data

• Hazardous Substances Data: 39161-85-8(Hazardous Substances Data)

Usage

Chemical Properties

Orange Crystalline Solid

Uses

Different sources of media describe the Uses of 39161-85-8 differently. You can refer to the following data:
1. 2-Mercaptophenylacetic acid is a useful synthetic intermediate for the preparation of novel antiinflammatory agents
2. A useful synthetic intermediate for the preparation of novel antiinflammatory agents.

InChI:InChI=1/C8H8O2S/c9-8(10)5-6-3-1-2-4-7(6)11/h1-4,11H,5H2,(H,9,10)

Upstream product

• 3342-78-7 2-(2-aminophenyl)acetic acid 
• 496-31-1 benzo[b]-2,3-dihydrothiophen-2-one 
• 18698-96-9 o-iodophenylacetic acid 
• 98437-23-1 benzo[b]thiophene-2-boronic acid 
• 79099-22-2 2-(2-(ethoxycarbonothioylthio)phenyl)acetic acid 
• 59-48-3 2-oxoindole 
• 493-57-2 benzo-[b]thiophene-2,3-dione 
• 140-89-6 potassium ethyl xanthogenate 
• 142336-19-4 o-Thiocyanatophenylessigsaeure 

Downstream Products

• 101110-71-8 bis(o-carboxymethylphenyl)disulfide 
• 172150-79-7 ethyl 2-(5-phenylthiazolidin-4-on-3-yl)isobutyrate 
• 1227413-19-5 2-(TIPSO-carbonylethyl)disulfanylphenylacetic acid 
• 2637-34-5 2-Sulfanylpyridine 
• 1334524-25-2 [2-({5-oxo-5-[(triisopropylsilyl)oxy]pentan-2-yl}disulfanyl)phenyl]acetic acid 
• 1363179-00-3 2-[2-(ethylsulfonyl)phenyl]-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 
• 1363179-47-8 2-(2-(ethylsulfonyl)phenyl)acetic acid 
• 1363179-45-6 ethyl 2-(2-(ethylsulfonyl)phenyl)acetate 
• 81549-19-1 Acetic acid [3-acetoxy-thiochromen-(2E)-ylidene]-phenyl-methyl ester 
• 81549-20-4 Acetic acid [3-acetoxy-thiochromen-(2Z)-ylidene]-phenyl-methyl ester 
• 81549-25-9 2-phenyl-2H-1-benzothiopyrano<3,4-b>indole 
• 81549-17-9 3-acetoxy-2-phenyl-2H-1-benzothiopyran 
• 81549-18-0 3-acetoxy-2-phenyl-4H-1-benzothiopyran 

Relevant articles and documents

In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-β-lactamase Inhibitors

Zinc ion-dependent β-lactamases (MBLs) catalyze the hydrolysis of almost all β-lactam antibiotics and resist the action of clinically available β-lactamase inhibitors. We report how application of in silico fragment-based molecular design employing thiol-

Novel amphiphilic PEG-hydroxycamptothecin conjugates as glutathione-responsive prodrug nanocapsules for cancer chemotherapy

A series of novel hydroxycamptothecin (HCPT) conjugates (13a–14d), which contained a polyethylene glycol moiety and disulfide bond, were designed and synthesized in five to six steps, with overall yields of 20–39%. The anticancer activities and toxicities of these new conjugates were evaluated using an in vitro MTT assay in K562, HepG2, and HT-29 cell lines and HUVECs. The conjugates displayed enhanced antitumor activity and reduced toxicity in comparison with their parent molecule, HCPT. Among these conjugates, compound 13a exhibited 100-fold better selectivity to the tumor cells than to HUVECs. TEM and DLS experiments demonstrated that 13a formed nanosized micelles with a diameter of approximately 200?nm in aqueous solution and that the conjugate could undergo glutathione-responsive degradation to release HCPT at the tumor site. The improved potency and reduced toxicity of these conjugates may be caused by the enhanced permeation and retention (EPR) effect of nanoparticles.

NOVEL COMPOUNDS

Novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR? provided by the present invention.